Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant

INTRODUCTION: Casirivimab-imdevimab, an antibody cocktail containing two severe acute respiratory syndrome coronavirus 2 neutralizing antibodies, reduces the viral load and the risk of coronavirus disease 2019 (COVID-19)-related hospitalization or death. The objective of this study was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyashita, Naoyuki, Nakamori, Yasushi, Ogata, Makoto, Fukuda, Naoki, Yamura, Akihisa, Ishiura, Yoshihisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132788/
https://www.ncbi.nlm.nih.gov/pubmed/35637130
http://dx.doi.org/10.1016/j.jiac.2022.05.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132788/
https://www.ncbi.nlm.nih.gov/pubmed/35637130
http://dx.doi.org/10.1016/j.jiac.2022.05.012

Ejemplares similares